A new drug-discovery wave is focusing beyond KRAS G12C, targeting broader KRAS-driven biology in cancers where the most famous mutation class has dominated the market. The coverage highlights research positioning these next-generation KRAS pathway strategies as a response to the limits of earlier approaches. For biotech stakeholders, this shift matters because KRAS-mutant disease remains common across pancreatic ductal adenocarcinoma and parts of colorectal and non-small-cell lung cancer. Programs that can engage KRAS variants or downstream dependencies could expand addressable populations beyond current covalent cohorts. While the underlying dataset details were not provided in the article excerpt, the theme is immediate: companies are trying to broaden efficacy footprints that have historically clustered around specific KRAS mutation subsets.